抗线粒体抗体阴性初级胆汁硬化与二次性Sjogren综合征:一个病例报告
Suman Acharya1, Suraj Shrestha2, Elisha Poddar2
1Department of Internal Medicine.
Annals of medicine and surgery (2012)
|November 2, 2023
概括
抗线粒体抗体阴性初级胆道胆炎 (AMA阴性PBC) 是罕见的,但与AMA阳性PBC具有共同的特征. 诊断依赖于病理学,与ursodeoxycholic酸的治疗是有效的,无论AMA状态.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 初级胆道胆炎 (PBC) 是一种免疫媒介的肝脏疾病.
- 抗线粒体抗体 (AMA) 是诊断特征,在大多数患者中都存在.
- 亚马阴性PBC是一种罕见的变体,通过病理特征诊断.
研究的目的:
- 呈现一种罕见的AMA阴性PBC病例.
- 突出AMA阴性PBC的诊断和治疗方面的考虑.
主要方法:
- 一个39岁患有Sjogren综合征的女性的病例报告.
- 关于AMA阴性PBC患病率和诊断的文献综述.
主要成果:
- 亚马阴性PBC约占病例的5%.
- 临床,生物化学和组织病理学特征在AMA阳性和AMA阴性PBC之间是相似的.
- 乌尔索多西胆酸是所有PBC患者的标准治疗方法.
结论:
- AMA 状态不会改变 PBC 的临床表现或治疗.
- 诊断AMA阴性PBC需要仔细的病理评估.
- 对于管理PBC来说,AMA的识别并不必不可少.
更多相关视频
相关概念视频
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...


